Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia
about
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaLarge granular lymphocytosis during dasatinib therapyActivating KIRs in Chronic Lymphoproliferative Disorder of NK Cells: Protection from Viruses and Disease Induction?Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemiaDasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerationsInterferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML PatientsRapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.Dasatinib promotes Th1-type responses in granzyme B expressing T-cellsDasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusionA molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitorsDistinctive clinical characteristics and favorable outcomes in patients with large granular lymphocytosis after allo-HCT: 12-year follow-up data.Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis.Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicityDasatinib in chronic myeloid leukemia: a review.Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents.Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib.Immunomodulatory effects of anti-angiogenic drugs.Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.State of the art in natural killer cell malignancies.Evolution of therapies for chronic myelogenous leukemia.Biological therapy and the immune system in patients with chronic myeloid leukemia.Novel immune modulators used in hematology: impact on NK cellsEver-advancing chronic myeloid leukemia treatment.Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia.Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells.Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib.Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph(+) acute lymphoblastic leukemia during second-generation tyrosine-kinase inhibitor therapy.Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib.Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study.Clinical Features, Pathogenesis, and Treatment of Large Granular Lymphocyte Leukemias.Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia.Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.Direct effect of dasatinib on signal transduction pathways associated with a rapid mobilization of cytotoxic lymphocytes.New hope for chronic myelogenous leukemia patients: dasatinib offers better efficacy with shorter treatment.Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches.Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia.Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study.
P2860
Q26749324-5DD70420-220B-448B-AEC7-247E545E75DCQ27012699-6C2E63AB-426D-43CA-86BD-82076B6084BAQ27013073-9E3A1BEC-C756-49CD-8501-B0F2BEE65425Q27027369-0A60829C-F425-4E4E-AFC7-F32E217E6BDDQ28079372-7BD50C02-96EF-48FC-A138-8C92A92E42A5Q28552307-EC5C28C4-5DF2-4105-A084-55C3E853C05EQ33404602-24D73409-C4AC-4FFA-AC49-F6A5ED948546Q33593877-2FCAF738-7773-4CE7-A01C-6724985EB38CQ33930605-37455237-B6FD-4FDC-9B22-43E6115AB7F5Q34289635-33A5349C-FDD3-4212-BC83-FDABCBFAACB1Q35804757-31DD6126-1E14-4D83-90F1-290F15538E28Q36356861-EFF6A403-4FD8-4F2E-9E7B-411481EB98ECQ37098840-0723860C-75C1-428B-8655-A8877772AC4FQ37352396-72B3AFBA-5885-40D9-BF66-4EBC0C853A99Q37523302-AC30E762-7735-410A-AF9A-A6147E1B2B11Q37763106-DE3416CC-6721-4F5D-B72C-2816A2FE97A4Q37771246-B3A9EB46-CEC2-4C96-AADC-0C3DBB625F15Q37847051-AA22D4E0-1C27-468E-847E-6B726D62DA03Q37918304-4A5B14DB-7ED0-41A5-B181-61BF3D2078B6Q37927210-6E1A944E-20B8-4D05-AEE6-E7A4C769F84CQ37966915-348466C9-CC3C-4CBC-9131-7DD8EFC5D3D1Q38015742-1979E1E2-B1B2-4B20-9E01-990E5DD47DB5Q38073760-7AAE9323-D209-40A7-9D31-C66718BBD53AQ38164565-8B5C0079-A866-4230-A4D8-47AE50134111Q39061903-8D290FB8-A569-4270-A16C-84E85992FAFCQ39168624-8B87FCB3-C7C1-400B-9ADC-B7CF3A8DAF50Q39379461-6DBC4A9B-F141-4D3A-8218-5E2F56E95B9BQ40196834-E35E0C49-1CCE-44CA-AC95-AA7D6427278AQ40297565-FDF12DA3-3D4A-4E8B-A4B4-041B54BBD882Q40679442-1883A7DE-3E7B-4D1F-89F7-F78EA4B15B46Q40807169-ACFDEC3E-55BE-41AE-8AB8-EEEA17AFA967Q41307812-932108CE-2B6B-484F-ADFA-9D268706E445Q41356321-70CCA122-0824-44B0-AFF2-3176E418D494Q41661752-3F5B059A-FCDB-4901-B636-27D04F5745CFQ41767329-F241BCCB-3F73-4B80-9C4E-E663C8783F2CQ42407714-3573583A-738F-4BA2-99CC-2EDC3E046A02Q42574009-50A1F21D-4561-4051-97B9-7C0F411EACD3Q44291160-FDFB1C18-4F83-4254-BF6F-56D035264DA7Q44679459-A349EA27-DB4D-438B-B990-03868A943978Q44690584-0A4DC469-703E-4A78-A8C0-427A61C11D1E
P2860
Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Natural killer or natural kill ...... a chromosome positive leukemia
@en
Natural killer or natural kill ...... chromosome positive leukemia.
@nl
type
label
Natural killer or natural kill ...... a chromosome positive leukemia
@en
Natural killer or natural kill ...... chromosome positive leukemia.
@nl
prefLabel
Natural killer or natural kill ...... a chromosome positive leukemia
@en
Natural killer or natural kill ...... chromosome positive leukemia.
@nl
P2093
P2860
P356
P1433
P1476
Natural killer or natural kill ...... a chromosome positive leukemia
@en
P2093
Chul Won Jung
Dong Hwan Kim
Hong Chang
Hyeoung-Joon Kim
Je-Jung Lee
Jeffrey H Lipton
Robert Sutherland
P2860
P304
P356
10.3324/HAEMATOL.13151
P577
2008-12-09T00:00:00Z